US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

21.26

+0.16000.76%

Post-market: 21.500.2400+1.13%16:07 EDT

Volume:587.42K

Turnover:12.45M

Market Cap:3.74B

PE:-17.04

High:21.36

Open:21.12

Low:20.94

Close:21.10

Loading ...

Overview Company News Filings

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

OneStream Is Maintained at Overweight by Morgan Stanley

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Here's Why Summit Therapeutics Stock Soared 15% on Friday

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Preliminary Results for the Year Ended 31 December 2024

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

OneStream CEO Thomas Shea to Assume Additional Role of President

MT Newswires Live

BRIEF-OneStream Co-Founder Craig Colby To Transition To Chief Success Officer Effective May 1, 2025 - SEC Filing

Onestream Inc: Co-Founder Craig Colby to Transition to Chief Success Officer Effective May 1, 2025 - SEC Filing

THOMSON REUTERS

Onestream Inc - Thomas Shea to Assume Role of President - SEC Filing

THOMSON REUTERS

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

OneStream Announces New ESG Reporting & Planning Solution to Help CFOs Navigate Evolving Reporting Demands

OneStream Is Maintained at Buy by Truist Securities

OneStream price target lowered to $27 from $37 at Truist

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

N-able Advances IT Operations and Security Operations with Built-in Vulnerability Management

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":21.26,"timestamp":1745956800000,"preClose":21.1,"halted":0,"volume":587421,"hourTrading":{"tag":"盘后","latestPrice":21.5,"preClose":21.26,"latestTime":"16:07 EDT","volume":6663,"amount":141651.63539399998,"timestamp":1745957229565},"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Post-Mkt","change":0.16,"latestTime":"04-29 19:07:32 EDT","open":21.12,"high":21.36,"low":20.94,"amount":12446409.44113,"amplitude":0.019905,"askPrice":24.65,"askSize":100,"bidPrice":12.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":4,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.1,"preHourTrading":{"tag":"盘前","latestPrice":21.01,"preClose":21.1,"latestTime":"04:37 EDT","volume":7,"amount":148.56999499999998,"timestamp":1745915844247},"postHourTrading":{"tag":"盘后","latestPrice":21.5,"preClose":21.26,"latestTime":"16:07 EDT","volume":6663,"amount":141651.63539399998,"timestamp":1745957229565},"volumeRatio":0.755198,"impliedVol":0.8449,"impliedVolPercentile":0.9468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.755198,"shares":176023203,"dividePrice":0,"high":21.36,"amplitude":0.019905,"preClose":21.1,"low":20.94,"week52Low":16.6942,"pbRate":"9.69","psRate":"7.65","week52High":35.39,"institutionHeld":0,"latestPrice":21.26,"eps":-1.247698,"divideRate":0,"volume":587421,"delay":0,"ttmEps":-1.247698,"open":21.12,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.34,"prevQuarterClose":21.34,"fiveDayClose":19.79,"twentyDayClose":21.34,"sixtyDayClose":29.78,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529803706","title":"AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803706","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803706?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:05","pubTimestamp":1745237101,"startTime":"0","endTime":"0","summary":"AstraZeneca Plc  on Monday released topline data from the DESTINY-Breast09 Phase 3 trial ofEnhertu either alone or in combination with pertuzumab versus standard of care THP  as a first-line treatment in patients with HER2-positive metastatic breast cancer.High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  compared to THP.Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings. HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2, affecting 15-20% of patients with metastatic breast cancer.While HER2-targeted therapies have improved outcomes, prognosis remains poor, with most patients experiencing disease progression within two years of 1st-line treatment with THP, which has been the standard of care for more than a dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-daiichi-sankyos-multi-billion-120501820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","BK4195","LU0320765992.SGD","LU2456880835.USD","OS","LU2462157665.USD","PFS","LU0889565916.HKD","BK4211","BK4568","BK4097","BK4588","LU2236285917.USD","BK4007","ADC","DSKYF","BK4080","LU1829250122.USD","BK4585","BK4231","LU0109394709.USD","DSNKY","LU2417539215.USD"],"gpt_icon":0},{"id":"2529803700","title":"ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803700","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803700?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:00","pubTimestamp":1745233200,"startTime":"0","endTime":"0","summary":"DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care. WILMINGTON, Del., April 21, 2025----Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU  in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival  compared to a taxane, trastuzumab and pertuzumab  as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.The PFS improvement was seen across all pre-specified patient subgroups with ENHERTU in combination with pertuzumab. The key secondary endpoint of overall survival  was not mature at the time of this planned interim analysis; however, interim OS data showed an early trend favoring the ENHERTU combination compared wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-110000627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2456880835.USD","BK4203","LU2417539215.USD","BK4080","OS","BK4211","BK4231","PFS","LU0109394709.USD","BK4568","LU2462157665.USD","ADC","BK4195","LU1829250122.USD","BK4585","LU0889565916.HKD","BK4225","BK4007","LU0320765992.SGD","BK4097","LU2236285917.USD","HR","BK4588","AZN"],"gpt_icon":0},{"id":"2528822190","title":"OneStream Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2528822190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528822190?lang=en_us&edition=fundamental","pubTime":"2025-04-17 00:21","pubTimestamp":1744820460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 12:21 ET (16:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2527228478","title":"Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2527228478","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527228478?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:57","pubTimestamp":1744815426,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101  in recurrent high-grade glioma , substantiating the patient benefit seen in the IPAX-1 study.IPAX-Linz is a single-arm Phase 2 investigator-initiated trial evaluating the safety, tolerability, and preliminary efficacyof TLX101 therapy in combination with external beam radiation therapy .TLX101  is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1, which is typically over-expressed in glioblastoma.The target patient population is patients at first or second recurrence with high-grade gliomas , including glioblastoma.Treatment with TLX101 was well tolerated, with no serious adverse events reported.Also Read: Vale Q1 Iron Ore Output Falls 4.5% Amid Heavy Rains, Copper And Nickel Output Gain. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival  of 12.4 months from the initiation of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-touts-encouraging-data-145706839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TLX","BK4097","OS"],"gpt_icon":0},{"id":"2527640471","title":"IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2527640471","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527640471?lang=en_us&edition=fundamental","pubTime":"2025-04-16 06:37","pubTimestamp":1744756620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April  16, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3062201/0/en/IPAX-Linz-Study-Reports-Promising-Efficacy-for-TLX101-Glioma-Therapy-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","ASX","BK4141","BK4181","BK4218","OS","INN","BK4526","BK4139","TLX","BK4097"],"gpt_icon":0},{"id":"2527276154","title":"Here's Why Summit Therapeutics Stock Soared 15% on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2527276154","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527276154?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:57","pubTimestamp":1744624620,"startTime":"0","endTime":"0","summary":"Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities maintained their positive outlook on the company.Both investment firms remain optimistic about Summit Therapeutics’ lead pipeline drug, ivonescimab. This drug was developed in collaboration with China-based Akeso, which is also its original developer. Summit in-licensed the right to develop and market the drug in 2022 across several territories, including the United States and Europe.Cantor reportedly reiterated its Overweight rating on SMMT after an SEC filing revealed that the company’s co-chief executive officer , Bob Duggan, exercised warrants to acquire nearly 4 million shares of the company. This transaction was executed about four years before the warrants expired at a strike price of $1.58 each. The analyst pointed out that this indicated a bullish signal for the stock.Another regulatory filing also revealed that the company’s other co-CEO, Zanganeh Mahk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-summit-therapeutics-stock-095700433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","BNTX","LU1571399168.USD","LU1934455194.USD","LU0203345920.USD","LU2361044949.HKD","OS","SMMF","LU0070302665.USD","LU0265550946.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0965508806.USD","LU0965509101.SGD","LU1069347547.HKD","PFS","TIL","LU0320765646.SGD","LU1066051811.HKD","BK4568","MRK","LU0265550359.USD","LU1929549753.HKD","LU2106854487.HKD","SG9999014559.SGD","LU1093756168.USD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU1116320737.USD","BK4195","LU1989772840.SGD","IE00BLSP4239.USD","LU0211331839.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU1941712348.USD","LU1162221912.USD","LU2488822045.USD","SMMT","BK4559","LU0266013472.USD","IE00BLSP4452.SGD","LU0203347892.USD","LU0965509283.SGD","LU1974910355.USD","LU2324357040.USD","LU1093756325.SGD","LU2468319806.SGD","LENZ","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2526647726","title":"IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER","url":"https://stock-news.laohu8.com/highlight/detail?id=2526647726","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526647726?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:00","pubTimestamp":1744376400,"startTime":"0","endTime":"0","summary":"First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy. THOUSAND OAKS, Calif., April 11, 2025 /PRNewswire/ -- Amgen  today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA  as a treatment for patients with small cell lung cancer  who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival  compared to local standard-of-care  chemotherapy.About IMDELLTRAIMDELLTRA is a first-in-class immunotherapy engineered byAmgen researchers that binds to both DLL3 on tumor cells and CD3 onT cells, activatingT cells to kill DLL3-expressing SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell.4,5DLL3 is a protein that is expressed on the surface of SCLC cells","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/imdelltra-demonstrated-superior-overall-survival-130000200.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imdelltra-demonstrated-superior-overall-survival-130000200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOC","BK4082","BK4581","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4198","IE00B19Z4B17.USD","LU0109394709.USD","LU0122379950.USD","LU2242652126.USD","LUNG","CRS","LU2089984988.USD","LU2468319806.SGD","LU0889565916.HKD","LU2112291526.USD","SG9999001440.SGD","BK4534","BK4213","IE00B2B36J28.USD","BK4588","IE00B66KJ199.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0289739699.SGD","AMGN","LU1023059063.AUD","BK4585","LU0320765992.SGD","LU1061106388.HKD","OS","IE00BJT1NW94.SGD","BK4139","LU1571399168.USD","IE0002141913.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE0009355771.USD","PI","LU2242646821.SGD","LU0868494617.USD","BK4599","BK4566","BK4006","LU1057294990.SGD","BK4533","BK4141","IE00B4R5TH58.HKD","LU1878469433.USD","BK4097"],"gpt_icon":0},{"id":"2526066623","title":"Preliminary Results for the Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2526066623","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526066623?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"April 11, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060077/0/en/Preliminary-Results-for-the-Year-Ended-31-December-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDRX","OS","BK4097","LCA","PFS","BK4195","BK4211"],"gpt_icon":1},{"id":"2526498953","title":"Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2526498953","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526498953?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:30","pubTimestamp":1744230600,"startTime":"0","endTime":"0","summary":"Amezalpat  is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma ; global investigator support in place. Awarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC. Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis ; data expected 2026. The company has not set a timetable for completion of the process for evaluating strategic alternatives and does not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process for evaluating strategic alternatives. If the process for evaluating strategic alterna","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempest-announces-plan-explore-strategic-203000016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","NCI","HCC","BK4202","BK4139","OS","BK4097","TPST"],"gpt_icon":0},{"id":"2526136772","title":"OneStream CEO Thomas Shea to Assume Additional Role of President","url":"https://stock-news.laohu8.com/highlight/detail?id=2526136772","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526136772?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:02","pubTimestamp":1744207341,"startTime":"0","endTime":"0","summary":"OneStream  said late Tuesday that Chief Executive Officer Thomas Shea will also serve as president, effective May 1.The software company said current President Craig Colby will transition to the role of \"chief success officer,\" also effective May 1.Shea, who is also the company's co-founder and board chairman, will not receive any additional compensation for the additional role of president, OneStream said.Price: 18.04, Change: +0.11, Percent Change: +0.59","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2526225840","title":"BRIEF-OneStream Co-Founder Craig Colby To Transition To Chief Success Officer Effective May 1, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526225840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526225840?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:14","pubTimestamp":1744143255,"startTime":"0","endTime":"0","summary":"BRIEF-OneStream Co-Founder Craig Colby To Transition To Chief Success Officer Effective May 1, 2025 - SEC FilingApril 8  - OneStream Inc OS.O:ONESTREAM INC: CO-FOUNDER CRAIG COLBY TO TRANSITION TO CHIEF SUCCESS OFFICER EFFECTIVE MAY 1, 2025 - SEC FILINGONESTREAM INC - THOMAS SHEA TO ASSUME ROLE OF PRESIDENT - SEC FILINGSource text: [ID:n0000950170-25-052053]Further company coverage: OS.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2526840412","title":"Onestream Inc: Co-Founder Craig Colby to Transition to Chief Success Officer Effective May 1, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840412?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:09","pubTimestamp":1744142967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2526411840","title":"Onestream Inc - Thomas Shea to Assume Role of President - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526411840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526411840?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:09","pubTimestamp":1744142967,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","IE00BFTCPJ56.SGD","LU1323610961.USD","IE0009355771.USD","IE0002141913.USD","IE00B2B36J28.USD","BMY","CRT","IE00BSNM7G36.USD","LU1261432733.SGD","LU0868494617.USD","LU1989771016.USD","LU1670710661.SGD","LU1868837136.USD","BK4124","ORR","BK4195","LU1868836757.USD","BK4144","BK4532","BK4211","LU1718418525.SGD","LU1074936037.SGD","BK4006","LU0225771236.USD","LU2133065610.SGD","LU1670710588.SGD","LU2242646821.SGD","TEN","HSCT","LU1032466523.USD","LU1585245621.USD","LU0225284248.USD","LU1670711123.USD","PFS","BK4132","LU0985481810.HKD","LU1868837300.USD","LU0114720955.EUR","HCC","LU0061475181.USD","LU1093756168.USD","VOD","CRC","LU2242652126.USD","LU1093756325.SGD","LU0237698245.USD","OS","BK4581","LU1670711040.USD"],"gpt_icon":0},{"id":"2525897392","title":"OneStream Announces New ESG Reporting & Planning Solution to Help CFOs Navigate Evolving Reporting Demands","url":"https://stock-news.laohu8.com/highlight/detail?id=2525897392","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525897392?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:00","pubTimestamp":1744117200,"startTime":"0","endTime":"0","summary":"UnifiedESG Planning and Reporting now supports Scope 1, 2 and 3 emissions frameworks. BIRMINGHAM, Mich., April 8, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions – including financial close, consolidation, reporting, planning and forecasting, today announced its new ESG Reporting & Planning solution. This solution enables OneStream customers to seamlessly collect, analyze, report and plan for ESG requirements – including Scope 1, 2 and 3 emissions – within OneStream's unified platform.OneStream's ESG Reporting & Planning solution unifies ESG data and processes in a single platform—empowering Finance leaders to link sustainability efforts to financial performance. With support for target setting, scenario modelling, and Scope 1, 2, and 3 reporting, it helps businesses meet global compliance and make data-driven decisions that guide business performance. Key ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-announces-esg-reporting-planning-130000683.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-announces-esg-reporting-planning-130000683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4097","ESG"],"gpt_icon":0},{"id":"2525443340","title":"OneStream Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2525443340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525443340?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:06","pubTimestamp":1744034760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 10:06 ET (14:06 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2525012882","title":"OneStream price target lowered to $27 from $37 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2525012882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525012882?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:31","pubTimestamp":1744025461,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on OneStream (OS) to $27 from $37 and keeps a Buy rating on the shares as part of a broader research note on...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-price-target-lowered-to-27-from-37-at-truist?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-price-target-lowered-to-27-from-37-at-truist?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2525018533","title":"OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525018533","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525018533?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020000,"startTime":"0","endTime":"0","summary":"OS Therapies applies for meeting per FDA suggestion received on April 2, 2025. Based on prior FDA guidance, greater than 200 suitable matched lung metastatic osteosarcoma patient records identified from leading oncology centers in the US, UK and France for inclusion in OST-400, a Retrospective Longitudinal Study of Recurrent Osteosarcoma after Resection in Children and Young Adults. \"We are excited to meet with the FDA – and commence market access discussions - the goal of receiving Accelerated Approval for a Biologics License Application of OST-HER2 in the prevention or delay of recurrence lung metastatic osteosarcoma by year-end 2025,\" said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. \"We believe that we have identified the comparator data necessary to address the comments from FDA regarding our prior BTD request. We expect this data will also be able support our application for Accelerated Approval. Our clinical and regulatory teams are diligently preparing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-requests-meeting-fda-100000983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4231","OSTX","BK4017","BK4080","DC","BK4139","OST","BK4148","ADC","BK4097"],"gpt_icon":0},{"id":"2525305056","title":"N-able Advances IT Operations and Security Operations with Built-in Vulnerability Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2525305056","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525305056?lang=en_us&edition=fundamental","pubTime":"2025-04-07 13:00","pubTimestamp":1744002000,"startTime":"0","endTime":"0","summary":"N-able UEM solutions now deliver a single, unified view to identify, prioritize, and report on vulnerabilities across all major operating systems. BURLINGTON, Mass., April 07, 2025---- -- N-able, Inc. , a global software company delivering a unified cyber resiliency platform to manage, secure, and recover, today announced the upcoming launch of its Vulnerability Management feature for their UEM  products, N-central and N-sight. The new built-in feature will allow organizations to identify, prioritize, remediate, and report on vulnerabilities across all major operating systems . With a single unified view, IT teams will gain continuous visibility to vulnerabilities, rapid prioritization, and can leverage automated workflows for remediation.There has been a rapid increase in both the volume of vulnerabilities and resulting attacks, posing a huge challenge for IT providers and SMEs alike. In 2025, an average of 133 CVEs  were disclosed daily—a reflection of the increasing complexity of mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/n-able-advances-operations-security-050000130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","NABL","OS"],"gpt_icon":0},{"id":"2525691739","title":"European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2525691739","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525691739?lang=en_us&edition=fundamental","pubTime":"2025-04-05 02:02","pubTimestamp":1743789775,"startTime":"0","endTime":"0","summary":"The European Commission on Friday approved AstraZeneca Plc  and Daiichi Sankyo's Enhertu  as a monotherapy for a type of breast cancer.The approval covers adult patients with unresectable or metastatic hormone receptor -positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.Also Read: FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients. The approval is based on results from the DESTINY-Breast06 Phase 3 trial.In the trial,Enhertushowed a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-nave HR-positive, HER2-low metastatic breast cancer with a median progression-free survival  of 13.2 months versus 8.1 months.In the overall trial population, the median PFS was 13.2 months in patients randomized toEnhertucompare","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-drug-regulator-approves-astrazenecas-180255396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2236285917.USD","BK4195","BK4585","LU0889565916.HKD","BK4203","LU0109394709.USD","BK4225","BK4568","OS","BK4007","LU2456880835.USD","LU1829250122.USD","LU2417539215.USD","BK4500","HR","BK4097","BK4588","PFS","LU2462157665.USD","ALK","BK4211","AZN","BK4008","LU0320765992.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1742529600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-28","current":-17.333565,"percent":0.89011,"low":-1655.61542,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"high":-14.493656,"avg":-429.05566,"sd":616.357181,"marketCap":3747533991},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-28","current":-17.333565,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"marketCap":3747533991}],"updateTime":1745925590335}}}